Coherus BioSciences Inc. (NASDAQ:CHRS) traded with an addition of $0.27 to close at $7.55 on Friday, an upside of 3.64 percent. An average of 2,239,310 shares of common stock have been traded in the last five days. There was a gain of $0.13 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 1,406,367 shares traded, while the 50-day average volume stands at 1,164,171.
CHRS stock has increased by 10.64% in the last month. The company shares reached their 1-month lowest point of $5.58 on 12/27/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $5.58 and a high of $17.19 in 52 weeks. It has reached a new high 2 times so far this year and lost -54.39% or -$8.43 in price. In spite of this, the price is down -56.11% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Coherus BioSciences Inc. (CHRS) stock’s beta is 0.92. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.72.
The quick ratio of Coherus BioSciences Inc. for the three months ended September 29 was 2.50, and the current ratio was 2.60, indicating that the company is able to meet its debt obligations. Its gross profit as reported stood at $268.96 million compared to revenue of $326.55 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Coherus BioSciences Inc.’s return on assets was -47.00%.
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$86.65 million in the quarter, while revenues were grew 55.53%. The analyst consensus anticipated Coherus BioSciences Inc.’s latest quarter earnings to come in at -$0.57 per share, but it turned out to be -$0.96, a -68.40% surprise. For the quarter, EBITDA amounted to -$79.45 million. Shareholders own equity worth $77.78 million.
From a technical analysis perspective, let’s take a brief look at Coherus BioSciences Inc. (CHRS) price momentum. RSI 9-day as of the close on 29 December was 58.87%, suggesting the stock is Neutral, with historical volatility in this time frame at 141.48%.
As of today, CHRS’s price is $6.63 +1.69% or $0.13 from its 5-day moving average. CHRS is currently trading +12.63% higher than its 20-day SMA and -31.87% lower than its 100-day SMA. However, the stock’s current price level is -8.33% below the SMA50 and -41.54% below the SMA200.
The stochastic %K and %D were 61.97% and 38.06%, respectively, and the average true range (ATR) was 0.65. With the 14-day stochastic at 84.63% and the average true range at 0.59, the RSI (14) stands at 55.20%. The stock has reached 0.13 on the 9-day MACD Oscillator while the 14-day reading was at -0.05.
UBS launched coverage on Coherus BioSciences Inc. (NASDAQ: CHRS) in its analyst report released on June 14, 2022. The firm assigned the stock a Neutral rating. The consensus rating for Coherus BioSciences Inc. (CHRS) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CHRS, while 3 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 4 others rate it as a “buy”.
What is CHRS’s price target for the next 12 months?
Analysts predict a range of price targets between $9.00 and $30.00, with a median target of $15.00. Taking a look at these predictions, the average price target given by analysts for Coherus BioSciences Inc. (CHRS) stock is $17.88.